Trump Wants Congress to Save Full-Spectrum CBD Before Fall Restrictions Kick In — Industry Is Cautiously Relieved

The hemp industry has spent months watching a clock tick down. Last November, Congress passed a funding bill that included new restrictions on hemp-derived products containing trace amounts of THC — setting a maximum of 0.4 milligrams of total THC per container, well below the trace levels found in most full-spectrum CBD products on the market. Absent a congressional fix, those restrictions take effect this fall, and the legal hemp products tens of millions of Americans currently buy at pharmacies, wellness shops, and online would effectively be recriminalized.

On April 23, President Donald Trump signaled publicly that he wants Congress to act before that happens.

“I am calling on Congress to update the Law to ensure that Americans can continue to access the full-spectrum CBD products they have come to rely on, and that help them,” Trump posted on Truth Social. “We must get this done RIGHT and FAST, especially for those who saw that CBD helps them. Plus, I am told it will also help our GREAT FARMERS, who we love, and will always be there for. Please get it done, and SOON.”

The post was direct, characteristically informal, and politically notable: a sitting Republican president explicitly endorsing the continuation of hemp-derived CBD access — including products with trace THC — at a moment when his own party’s legislative record has moved in the opposite direction.

The Contradiction at the Center

What makes Trump’s post significant is the tension it names without quite resolving.

Last fall’s Farm Bill funding rider — passed with bipartisan support — set the 0.4 mg THC cap specifically to address concerns about delta-8 THC, THCA, and other intoxicating hemp derivatives that have proliferated since the 2018 Farm Bill legalized hemp production. The intent was consumer protection and market guardrails. The effect, if implemented, is that products with trace levels of THC — including many broad-spectrum and full-spectrum CBD products that don’t produce any intoxicating effect — would be treated as federally illegal.

The President’s post suggests he views that as the wrong outcome. “ONE in FIVE adults have used it in the past year, and many say it improved their chronic pain enormously,” Trump wrote. “Hemp-derived CBD has made a HUGE difference for so many people.”

NORML, which has consistently urged Congress to distinguish between intoxicating hemp derivatives and non-intoxicating CBD products, welcomed the statement. The organization has argued that the THC cap approach is a blunt instrument that sweeps up legitimate wellness products alongside the delta-8 gummies and THCA flower that regulators are actually concerned about.

A Competing Medicare Pilot Adds Complexity

Trump’s post isn’t the only federal signal pulling in this direction. In March, the Centers for Medicare & Medicaid Services launched a pilot program authorizing participating Accountable Care Organizations and oncology programs to provide patients access to eligible hemp products containing up to 3 mg of THC — a ceiling that’s actually seven times higher than the November restriction allows.

That policy contradiction — CMS authorizing Medicare-eligible hemp products with 3 mg THC while a congressional rider sets a 0.4 mg cap for all sales — is exactly the kind of regulatory incoherence that the industry has been trying to get Congress to address. Trump’s intervention, at least rhetorically, points toward resolving it in the industry’s favor.

What Congress Would Actually Have to Do

Fixing this legislatively is not simple. The restriction is embedded in a continuing resolution funding bill, not standalone hemp legislation. Repealing or modifying it requires either:

1. A new piece of standalone hemp legislation — unlikely to pass through regular order on a tight timeline 2. An amendment attached to the next spending bill or Farm Bill reauthorization 3. A targeted rider on another must-pass vehicle

House lawmakers actually attempted the third route this week: an amendment to delay the implementation of the hemp restriction was reportedly put forward but then withdrawn before a vote could be taken, suggesting the political coalition to carry it hasn’t fully coalesced yet.

The Senate side hasn’t moved formal legislation either. Without a clear legislative vehicle, Trump’s Truth Social urgency may not translate into floor action before the fall deadline.

Why the Industry Is Cautiously Optimistic — and Why ‘Cautiously’ Matters

For hemp operators, Trump’s post represents genuine good news in the sense that presidential attention on a regulatory issue usually precedes some kind of staff-level action, even if the tweet itself doesn’t change anything. White House involvement can unstick legislative negotiations that have been going nowhere.

But the hemp industry has seen presidential enthusiasm for its products before without durable policy outcomes. The 2018 Farm Bill, which legalized hemp, generated enormous optimism about a clear federal regulatory framework for CBD — and that framework never fully materialized. The FDA spent years deliberating over CBD regulations that never arrived. What the industry got instead was a patchwork of state rules and an ambiguous federal posture that left enforcement spotty but businesses in legal gray areas.

Hemp companies building business models around full-spectrum products need a legislative fix, not a social media post. If Congress doesn’t act by the fall, some operators are likely to face supply chain disruptions, reformulation costs, and potential enforcement actions regardless of what the President says on Truth Social.

The clock is still running. Trump has given the industry something to point to. Whether Congress hears it — and acts in time — remains very much an open question.

Morgan Ellis covers hemp, CBD, and agricultural cannabis policy for CannabisInquirer.com.